Japan's Ministry of Health, Labor and Welfare (MHLW) has granted manufacturing and marketing approval for Andembry ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...

Gwangju Global Motors assembly workers strike; India: Samsung household appliance factory workers in Tamil Nadu remain on strike; Pakistan: National strike by Utility Store Corporation workers; ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...

Another ASX 200 blue chip share that could be a top buy for an SMSF is CSL. It is the biotechnology giant behind the CSL ...

Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...

Albumin Market Trends 2025 Significant surge in non-therapeutic application of albumin, increasing production of immunoglobulins & plasma c ...

What is ASX reporting season? Reporting or earnings season refers to the time of year when most publicly listed companies release their financial results to the market and announce the dividends ...